Sign In
NASDAQ:CORT
Corcept Therapeutics Incorporated Stock Earnings Reports
$58.66
+1.07 (+1.86%)
At Close: Mar 21, 2025
Corcept Therapeuticsorporated Earnings Calls
Q4 2024
Missed
$0.260 (-29.73%)
| Release date | Feb 26, 2025 |
| EPS estimate | $0.370 |
| EPS actual | $0.260 |
| EPS Surprise | -29.73% |
| Revenue estimate | 200.115M |
| Revenue actual | 181.89M |
| Revenue Surprise | -9.11% |
Q3 2024
Beat
$0.410 (46.43%)
| Release date | Oct 30, 2024 |
| EPS estimate | $0.280 |
| EPS actual | $0.410 |
| EPS Surprise | 46.43% |
| Revenue estimate | 198.02M |
| Revenue actual | 182.546M |
| Revenue Surprise | -7.81% |
Q2 2024
Beat
$0.320 (39.13%)
| Release date | Jul 29, 2024 |
| EPS estimate | $0.230 |
| EPS actual | $0.320 |
| EPS Surprise | 39.13% |
| Revenue estimate | 162.08M |
| Revenue actual | 163.796M |
| Revenue Surprise | 1.06% |
Q1 2024
Beat
$0.250 (13.64%)
| Release date | May 01, 2024 |
| EPS estimate | $0.220 |
| EPS actual | $0.250 |
| EPS Surprise | 13.64% |
| Revenue estimate | 141.2M |
| Revenue actual | 146.808M |
| Revenue Surprise | 3.97% |
Last 4 Quarters for Corcept Therapeuticsorporated
Below you can see how CORT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | May 01, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $23.88 |
| EPS estimate | $0.220 |
| EPS actual | $0.250 |
| EPS surprise | 13.64% |
| Date | Price |
|---|---|
| Apr 25, 2024 | $22.21 |
| Apr 26, 2024 | $22.80 |
| Apr 29, 2024 | $23.37 |
| Apr 30, 2024 | $23.32 |
| May 01, 2024 | $23.88 |
| May 02, 2024 | $25.06 |
| May 03, 2024 | $24.52 |
| May 06, 2024 | $23.97 |
| May 07, 2024 | $24.48 |
| 4 days before | 7.52% |
| 4 days after | 2.51% |
| On release day | 4.94% |
| Change in period | 10.22% |
Q2 2024
Beat
| Release date | Jul 29, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $36.53 |
| EPS estimate | $0.230 |
| EPS actual | $0.320 |
| EPS surprise | 39.13% |
| Date | Price |
|---|---|
| Jul 23, 2024 | $34.56 |
| Jul 24, 2024 | $34.48 |
| Jul 25, 2024 | $34.87 |
| Jul 26, 2024 | $35.60 |
| Jul 29, 2024 | $36.53 |
| Jul 30, 2024 | $36.12 |
| Jul 31, 2024 | $38.67 |
| Aug 01, 2024 | $37.94 |
| Aug 02, 2024 | $35.30 |
| 4 days before | 5.70% |
| 4 days after | -3.37% |
| On release day | -1.12% |
| Change in period | 2.14% |
Q3 2024
Beat
| Release date | Oct 30, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $46.89 |
| EPS estimate | $0.280 |
| EPS actual | $0.410 |
| EPS surprise | 46.43% |
| Date | Price |
|---|---|
| Oct 24, 2024 | $47.24 |
| Oct 25, 2024 | $47.28 |
| Oct 28, 2024 | $48.34 |
| Oct 29, 2024 | $48.21 |
| Oct 30, 2024 | $46.89 |
| Oct 31, 2024 | $48.97 |
| Nov 01, 2024 | $47.62 |
| Nov 04, 2024 | $50.06 |
| Nov 05, 2024 | $52.14 |
| 4 days before | -0.741% |
| 4 days after | 11.20% |
| On release day | 4.44% |
| Change in period | 10.37% |
Q4 2024
Missed
| Release date | Feb 26, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $63.37 |
| EPS estimate | $0.370 |
| EPS actual | $0.260 |
| EPS surprise | -29.73% |
| Date | Price |
|---|---|
| Feb 20, 2025 | $65.08 |
| Feb 21, 2025 | $63.54 |
| Feb 24, 2025 | $61.81 |
| Feb 25, 2025 | $61.23 |
| Feb 26, 2025 | $63.37 |
| Feb 27, 2025 | $59.85 |
| Feb 28, 2025 | $60.58 |
| Mar 03, 2025 | $59.07 |
| Mar 04, 2025 | $55.99 |
| 4 days before | -2.63% |
| 4 days after | -11.65% |
| On release day | -5.55% |
| Change in period | -13.97% |
Corcept Therapeuticsorporated Earnings Call Transcript Summary of Q4 2024
2025 Revenue Guidance
Expected between $900 million and $950 million.
Net Income
$141 million for 2024, a 33% year-over-year increase.
Cash and Investments
$603 million as of December 31, 2024, up from $425 million.
Stock Buyback
$38 million spent on repurchasing common stock.
Cushing's Syndrome Developments
- Korlym Growth: Significant increase in new prescribers and patients; physicians are increasingly aware of hypercortisolism.
- NDA Submission: Submitted an NDA for relacorilant on December 30, 2024, based on positive data from pivotal studies.
- Efficacy of Relacorilant: Showed significant improvements in clinical measures like blood pressure and blood sugar levels in studies.
Ongoing Studies
- ROSELLA Study: In progress for treatment of platinum-resistant ovarian cancer with relacorilant, showing promising results.
- Change to dual primary endpoints (progression-free survival and overall survival) has been agreed upon with the FDA.
- Anticipate progression-free survival results by the end of the current quarter.
- MOMENTUM Study: Planned to start soon to establish the prevalence of hypercortisolism in patients with resistant hypertension.
- MASH Study: Developing miricorilant as a treatment for metabolic dysfunction-associated steatosis (MASH) with positive Phase Ib results.
Future Growth Strategies
- Strong confidence in further revenue growth due to increased screening for hypercortisolism and effective treatment options available with Korlym and relacorilant.
- Anticipation of fulfilling the market potential for hypercortisolism to drive revenues to between $3 billion and $5 billion in the coming 3 to 5 years.
Regulatory Outlook
- No AdCom expected for relacorilant given recent drug approvals in the same category, indicating confidence in the safety and efficacy profile.
Investor Implications
- Significant financial growth and robust pipeline indicate strong potential for future revenue increases.
- Clinical trial results and ongoing research should keep investors aware of upcoming milestones that could impact stock performance.
- Focus on increasing awareness and diagnosis of hypercortisolism could expand the patient base and market share.
Corcept Therapeuticsorporated Earnings History
Earnings Calendar
FAQ
When is the earnings report for CORT?
Corcept Therapeutics Incorporated (CORT) has scheduled its earnings report for May 07, 2025 after the markets close.
What is the CORT price-to-earnings (P/E) ratio?
CORT P/E ratio as of Mar 21, 2025 (TTM) is 42.56.
What is the CORT EPS forecast?
The forecasted EPS (Earnings Per Share) for Corcept Therapeutics Incorporated (CORT) for the first fiscal quarter 2025 is $0.200.
What are Corcept Therapeutics Incorporated's retained earnings?
On its balance sheet, Corcept Therapeutics Incorporated reported retained earnings of $181.89 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
